Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net (loss) income		$ (35,112)	$ 69,780	$ (150,262)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization expense		35,422	47,105	56,809
Income from equity method investments		(5,296)	0	0
Amortization of debt costs		20,751	23,199	13,160
Stock-based compensation		4,563	6,808	8,359
Long-lived asset impairments		0	38,236	457,794
Gain on convertible debt and debt refinancing costs		(3,214)	0	(10,996)
Loss on debt refinancing		0	16,740	0
Loss on net asset exchange for the formation of the joint ventures		21,293	0	0
Loss (gain) on forward contracts for the issuance of convertible preferred stock		16,787	(88,942)	0
Third-party fees associated with refinancing		0	(16,322)	0
Distributions received from equity method investments		3,856	0	0
Deferred income tax expense (benefit)		20,596	(23,265)	(191,578)
Other		2,467	(513)	(314)
Changes in assets and liabilities:
Increase in receivables		(4,411)	(1,358)	(448)
Decrease in inventory		18,018	16,757	72,903
(Increase) decrease in prepaid and other current assets		(11,148)	14,687	(5,529)
Increase (decrease) in accounts payable		44,497	(3,351)	(23,960)
(Decrease) increase in deferred revenue and accrued liabilities		1,006	1,252	(10,181)
Decrease in net lease liabilities		(31,880)
Other changes in assets and liabilities		(1,675)	(4,945)	4,751
Net cash provided by operating activities		96,520	95,868	220,508
Cash flows from investing activities:
Capital expenditures		(15,151)	(18,981)	(32,123)
Refranchising proceeds, net of store acquisition costs		2,395	2,514	1,994
Capital contribution to the joint ventures		(13,079)	0	0
Proceeds from the assets exchange for the formation of the joint ventures		99,221	0	0
Proceeds from the sale of Lucky Vitamin		0	0	6,367
Net cash provided by (used in) investing activities		73,386	(16,467)	(23,762)
Cash flows from financing activities:
Borrowings under Revolving Credit Facility		22,000	410,000	317,500
Payments on Revolving Credit Facility		(22,000)	(410,000)	(444,500)
Proceeds from the issuance of convertible preferred stock		199,950	100,000	0
Convertible notes repurchase		(24,708)	0	0
Original issuance discount and revolving credit facility fees		(10,365)	(35,235)	0
Fees associated with the issuance of convertible preferred stock		(12,814)	(3,587)	0
Minimum tax withholding requirements		(233)	(296)	(253)
Net cash used in financing activities		(119,256)	(75,768)	(168,106)
Effect of exchange rate changes on cash and cash equivalents		(828)	(410)	897
Net increase in cash and cash equivalents		49,822	3,223	29,537
Beginning balance, cash and cash equivalents		67,224	64,001	34,464
Ending balance, cash and cash equivalents		117,046	67,224	64,001
Cash (received) paid during the period for:
Income taxes	[1]	13,808	(3,841)	35,476
Interest		83,284	104,342	51,205
Non-cash investing activities:
Capital expenditures in current liabilities		1,373	1,238	1,683
Net assets contributed to the joint ventures		202,487	0	0
Non-cash financing activities:
Issuance of shares associated with exchange of convertible senior notes		0	0	71,670
Original issuance discount		0	11,445	0
Tranche B-1 Term Loan
Cash flows from financing activities:
Payments on Term Loans		(147,312)	(4,550)	(40,853)
Tranche B-2 Term Loan
Cash flows from financing activities:
Payments on Term Loans		$ (123,774)	$ (132,100)	$ 0

[1]     * Includes a $12.4 million tax refund received in the fourth quarter of 2018.